N-hydroxy-2-fluorenylacetamide, an active intermediate of the mammary carcinogen N-hydroxy-2-fluorenylbenzenesulfonamide.
The mechanism of mammary carcinogenesis by N-hydroxy-2-FBS, a highly potent mammary carcinogen for the female rat by ip administration, has been investigated. Previous work in vivo indicating hydrolytic cleavage of the nitrogen-sulfur bond has been confirmed with the use of sonicates of mammary gland. One of the products of the hydrolysis was N-hydroxy-2-FA identified by its conversion to 2-FA. Since carcinogenicity tests by local application showed that N-hydroxy-2-FA was not carcinogenic for the mammary gland, desulfonylation of N-hydroxy-2-FBS by mammary gland does not account for mammary carcinogenesis. N-Hydroxy-2-FBS applied directly to the mammary gland was not carcinogenic and 2-nitrosofluorene, the product of the spontaneous decomposition of N-hydroxy-2-FBS, exhibited only weak carcinogenicity upon local application. In contrast, N-hydroxy-2-FAA, a urinary metabolite of N-hydroxy-2-FBS, was highly carcinogenic by local application and very likely mediates the action of N-hydroxy-2-FBS. A metabolic pathway for the conversion of N-hydroxy-2-FBS to N-hydroxy-2-FAA is presented. This pathway involves the intermediate formation, by mammary gland or liver, of N-hydroxy-2-FA. The site of the subsequent acetylation of the hydroxylamine is unknown at present although the mammary gland appears to be excluded.